Cellectar Biosciences Provides Phospholipid Drug Conjugate

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cellectar Biosciences Provides Phospholipid Drug Conjugate (PDC) Platform Development Update

MADISON, Wis., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB ), an oncology-focused biotechnology company, today provides an update on its recently initiated Phospholipid Drug Conjugate (PDC) chemotherapeutic program, CLR CTX.

PDCs are a new class of small-molecules that employ Cellectar's extensively validated phospholipid ether-based cancer targeting and delivery vehicle. The PDC platform possesses the ability to link diverse oncologic payloads for targeted delivery to a broad range of cancers.

The objective of the CLR CTX program is to develop PDC chemotherapeutics through conjugation of our delivery vehicle and multiple non-targeted anti-cancer agents to improve therapeutic indices and expand potential indications through the targeted delivery of chemotherapeutic payloads.

"The potential advantages of drug candidates developed using the PDC delivery platform over classic cytotoxic approaches are broad-band tumor targeting, including brain metastases, and prolonged tumor cell retention, both of which have been validated by human imaging. Further, PDC delivery technology has demonstrated the ability to target human glioma stem cells ex vivo , suggesting the potential to provide targeted delivery of therapeutic agents to cancer stem cells," said John S. Kuo, MD, PhD, FAANS, FACS, Associate Professor of Neurological Surgery and Human Oncology (Tenure) Director, Comprehensive Brain Tumor Program Chair, CNS Tumors Working Group, Carbone Cancer Center, Center for Stem Cell and Regenerative Medicine at the University of Wisconsin-Madison.

CLR CTX Preclinical Update

The company introduced its Phospholipid Drug Conjugate (PDC) platform for the targeted delivery of chemotherapeutics during its second quarter financial results call in August, 2015. Since then the company has completed the first phase of its PDC chemotherapeutic preclinical proof of concept research, including in vitro evaluation of multiple conjugated paclitaxel analogs. A key outcome of this evaluation was the identification of a lead paclitaxel analog, CLR 1603-PTX, for advancement to in vivo studies. Further details about the results of CLR 1603-PTX in vitro evaluation will be presented during the company's third quarter financial results call later this month.  

"The sense of urgency demonstrated by our R&D team and the resulting progress with our CLR CTX program since we announced it two months ago is reflective of the potential of our PDC platform to create new targeted treatments for cancer," said Jim Caruso, president and CEO of Cellectar Biosciences. "To date, we have successfully developed multiple conjugated paclitaxel analogs, completed necessary in vitro work and are now advancing to in vivo studies."

CLR 1603-PTX in vivo safety and efficacy evaluation will now be conducted in animal tumor models in order to demonstrate the chemotherapeutic payload targeting efficacy of the PDC delivery platform.

About Phospholipid Drug Conjugates (PDCs)

Cellectar's PDC platform has demonstrated highly selective cancer targeting both preclinically in over 60 in vivo cancer models, and subsequently confirmed clinically in over 10 cancer types. The platform's payload diversity has been validated using cytotoxic radioisotopes for cancer therapy; PET imaging isotopes for cancer imaging; fluorophores for image-guided surgery, and now the company plans to expand its payload portfolio to chemotherapeutics with further preclinical study of paclitaxel and other non-targeted anti-cancer agents with both in-house and collaborative R&D efforts.

Cellectar's lead PDC is CLR 131. Its payload is iodine-131, a proven cytotoxic radioisotope that is used primarily for thyroid cancer treatment. The company initiated a disease-specific Phase 1 dose escalation study in patients with relapsed or refractory multiple myeloma this past April, and has been granted orphan drug designation. The company expects to evaluate cohort 1 and initiate cohort 2 during the first half of 2016. The primary objective of the study is to assess the safety and tolerability of CLR 131 in this patient population with secondary objectives of establishing the recommended Phase 2 dose and characterizing therapeutic activity.

About Cellectar Biosciences, Inc. Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase 1 study in patients with relapsed or refractory multiple myeloma. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1603-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For additional information please visit www.cellectarbiosciences.com .

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2014. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

INVESTOR AND MEDIA CONTACT: Jules Abraham JQA Partners 917-885-7378

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 119

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
AI Pushes Asset Managers Towards New Investment Growth

Updated Category News Views 89

AI: A Double-Edged Sword for Asset Managers Peeled straight from the heart of New York's financial buzz, AI is changing the game for asset and wealth managers. Now, we ain’t talking about some futuristic sci-fi scene, but real-world shifts that are scratching their way into boardrooms. Nearly 80% of firms playing the AI card see a sweet lift in productivity and...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Surgical Tooth Extraction: When It’s Necessary

Updated Category News Views 24

Unpacking the Complexities of Tooth Extraction Ever wonder why some tooth extractions are a stroll in the park while others dive straight into surgical territory? It's all about positioning, condition, and what's lurking underneath. Thanks to Dr. Yadira Cardona-Rohena of Hamilton Mill Oral & Facial Surgery, we’ve got the lowdown. The Need for Skilled Surgical Techniques...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 183

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 155

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 106

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 52

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading

Top 5 Most Recently Viewed Articles

Amazon Shows Potential for Growth Amid AWS Expansion Strategies

Updated Category News Views 178

Amazon's Current Market Position Amazon (NASDAQ: AMZN) is currently trading around $239–$240, showing slight gains from the previous close of $239.16. The stock is displaying limited intraday fluctuations within the $237.5–$241 range. Over the past year, this stock has oscillated between $161.43 and $258.60, placing it in the upper half of its 52-week range but still...

Continue Reading
Richmond Mutual and Farmers Bancorp Merge for Greater Growth

Updated Category News Views 173

Significant Merger Between Richmond Mutual and Farmers Bancorp Richmond Mutual Bancorporation, Inc. (NASDAQ: RMBI) recently announced a promising merger with The Farmers Bancorp. This strategic alliance aims to create a substantial community bank boasting assets totaling $2.6 billion, complemented by a network of 24 branches across key markets. The merger signals an...

Continue Reading
Exciting New Housing Development Launching Near Winston-Salem

Updated Category News Views 183

New Housing Opportunities from Century Communities Century Communities, Inc. (NYSE: CCS), recognized as a leading national homebuilder, is excited to announce an upcoming addition to its Century Complete brand. A new community named Woodford is set to emerge, providing affordable housing options in Thomasville, North Carolina, with homes starting in the high $200s. This...

Continue Reading
HashFly Unveils CloudMining+™: Your Gateway to Easy Crypto Profit

Updated Category News Views 102

HashFly Introduces CloudMining+™ for Effortless Crypto Earnings HashFly has launched an innovative solution called CloudMining+™, aimed at making cryptocurrency more accessible for all. This platform provides users with an exciting opportunity to earn daily crypto returns with absolutely no technical expertise required. Users can also enjoy a $10 sign-up bonus simply...

Continue Reading
Understanding the iLearningEngines Legal Controversy and Impact

Updated Category News Views 174

The Legal Battle Involving iLearningEngines iLearningEngines has recently found itself in troubled waters due to a securities fraud class action lawsuit filed in a U.S. District Court. This accusation could have significant consequences for the company and its investors. Background of iLearningEngines and the Lawsuit iLearningEngines, recognized as a prominent player in...

Continue Reading